In last trading session, Viridian Therapeutics Inc (NASDAQ:VRDN) saw 0.52 million shares changing hands with its beta currently measuring 0.62. Company’s recent per share price level of $13.50 trading at -$0.06 or -0.44% at ring of the bell on the day assigns it a market valuation of $1.10B. That closing price of VRDN’s stock is at a discount of -101.48% from its 52-week high price of $27.20 and is indicating a premium of 26.67% from its 52-week low price of $9.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.02 million shares which gives us an average trading volume of 971.51K if we extend that period to 3-months.
For Viridian Therapeutics Inc (VRDN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.24. Splitting up the data highlights that, out of 11 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Viridian Therapeutics Inc (NASDAQ:VRDN) trade information
Upright in the red during last session for losing -0.44%, in the last five days VRDN remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $13.50 price level, adding 7.6% to its value on the day. Viridian Therapeutics Inc’s shares saw a change of -29.58% in year-to-date performance and have moved 2.82% in past 5-day. Viridian Therapeutics Inc (NASDAQ:VRDN) showed a performance of -4.66% in past 30-days. Number of shares sold short was 10.16 million shares which calculate 12.4 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20.5 to the stock, which implies a rise of 34.15% to its current value. Analysts have been projecting 20.5 as a low price target for the stock while placing it at a high target of 20.5. It follows that stock’s current price would drop -51.85% in reaching the projected high whereas dropping to the targeted low would mean a loss of -51.85% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 31.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -6.05% while estimates for its earnings growth in next 5 years are of 23.74%.
Viridian Therapeutics Inc (NASDAQ:VRDN)’s Major holders
Insiders are in possession of 0.12% of company’s total shares while institution are holding 116.31 percent of that, with stock having share float percentage of 116.45%. Investors also watch the number of corporate investors in a company very closely, which is 116.31% institutions for Viridian Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at VRDN for having 9.57 million shares of worth $124.55 million. And as of 2024-06-30, it was holding 14.9924 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 4.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4758 of outstanding shares, having a total worth of $62.1 million.
On the other hand, Fidelity Select Portfolios-Health Care Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 2.3 shares of worth $30.99 million or 2.82% of the total outstanding shares. The later fund manager was in possession of 2.22 shares on Dec 31, 2024 , making its stake of worth around $29.96 million in the company or a holder of 2.72% of company’s stock.
